🎧 We loved this recent BBC Radio interview with Professor Siobhan Quenby MBE, who is leading the clinical trial of our progesterone-loaded Callavid at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust. 🔗 Listen to the clip: https://lnkd.in/e9GkFDaD Professor Quenby shares how our pioneering drug delivery technology could support women globally experiencing threatened miscarriage — …

Trust leads clinical trial of pioneering product to tackle threatened miscarriage 8 April 2025 Experts from University Hospitals Coventry and Warwickshire (UHCW) NHS Trust are to lead a clinical trial of a novel device aimed at addressing threatened miscarriage. More than 150,000 women a year in the UK could be helped by Callavid® which is designed …

[From NIHR: National Institute for Health and Care Research] We have awarded £1 million in funding to a first of its kind technology that’s being trialled to address threatened miscarriage. Currently, over 150,000 women in the UK experience threatened miscarriage a year. If approved, the device would become the world’s first drug-device combination to treat …

Pioneering technology to address threatened miscarriage secures £1 million funding and moves towards clinical trials • Scientists developing a pioneering device designed to address threatened miscarriage have secured £1 million in NIHR funding to begin clinical trials • Designed to deliver vital doses of progesterone, the Callavid® device stands to help over 150,000 women each …

We’ve achieved some exciting IP milestones for Calla Lily Clinical Care; making strong progress in building a robust IP strategy and IP portfolio to protect and advance our innovations in women’s health. 💥 China Patent Grant for our Drug Delivery Device 🌏 At long last, one of our vaginal drug delivery applications in China has …

Our co-founders Lara and Thang have been named in the annual ‘200 Trailblazing Leaders in Women’s Health and FemTech’ for the second year running.  It’s a real who’s who of the influential leaders working to improve the access and quality of healthcare for women worldwide.  We’re delighted at the recognition for Lara & Thang and …

🔊 Our co-founder, Dr Lara Zibners shares candid insights in a compelling podcast interview with Femmehealth Ventures. If you’ve ever thought, “There has to be a better way,” when it comes to drug delivery for women’s health, this episode is a must-listen. Lara shares her personal journey through IVF, the challenges of existing solutions, and …

We’re pleased to announce the award of a regulatory affairs grant as part of the MedTech Accelerator Rapid Regulatory Support (MARRS) Programme received from CPI in partnership with the UK Government’s Office of Life Sciences (Department for Science, Innovation and Technology). 🔬 Funding helps SMEs access external regulatory guidance and support, helping them accelerate the …

We’re delighted to see Calla Lily Clinical Care showcased in the latest print edition of Forbes France! This came from being recognised as one of the top startups at the MedFemTech Congress in Paris earlier this year. We’re always grateful for press coverage as it not only highlights our dedication but also elevates awareness around …

Congrats to our co-founders Dr. Lara Zibners and Thang Vo-Ta on being named in the annual 200 Trailblazing Leaders in Women’s Health and FemTech.  It’s a real who’s who  of the influential leaders working to improve the access and quality of healthcare for women worldwide. We’re delighted for the recognition of Lara, Thang and of …